BioMarin Pharmaceutical's GAAP net income for 6 months of 2023 was $106.89 million, down 28% from $148.46 million in the prior year. Revenue increased 13.2% to $1.192 billion against $1.053 billion a year earlier.

BioMarin Pharmaceutical's GAAP net income for 2022 was $149.56 million, against a loss of $82.34 million in the previous year. Revenue increased 13.5% to $2.096 billion from $1.846 billion a year earlier.

BioMarin Pharmaceutical's GAAP net income for 9 months of 2022 was $141.81 million, compared to a loss of $6.18 million in the previous year. Revenue increased by 11.6% to $1.559 billion from $1.397 billion a year earlier.

BioMarin Pharmaceutical's GAAP net income for 6 months of 2022 was $148.46 million, up 389.8% from $30.31 million in the previous year. Revenue increased 6.6% to $1.053 billion from $0.988 billion a year earlier.